Spectrofluorometric Analysis of New-Generation Antidepressant Drugs in Pharmaceutical Formulations, Human Urine, and Plasma Samples

Table 6

Evaluation of accuracy and precision of the proposed method in plasma.

Amount added (ng/μL)	Intraday		Interday
	Found	Recovery	Found	Recovery
	(ng/μL) ± SD^1	± RSD^3 (%)	(ng/μL) ± SD^1	± RSD^3 (%)
SER
10	08.75±0.102	87.50±1.30	08.90±0.081	89.0±1.06
50	48.37±0.004	96.74±3.16	47.68±0.017	95.36±4.67
100	97.23±0.103	97.23±4.98	96.83±0.252	96.83±5.25
PAR
10	08.01±0.107	80.10±1.30	08.35±0.106	83.50±2.18
50	48.69±0.025	97.38±4.04	47.67±0.045	95.34±4.19
100	98.28±0.120	98.28±5.10	96.67±0.110	96.67±5.12
CIT
10	08.36±0.020	83.60±2.19	07.09±0.184	70.90±1.70
50	48.06±0.084	96.12±3.30	48.05±0.062	96.10±2.50
100	98.95±0.172	98.95±4.67	97.51±0.074	97.51±4.79
VLF
10	08.84±0.094	88.40±2.17	07.70±0.074	77.0±2.15
50	49.77±0.108	99.54±2.98	47.82±0.096	95.64±3.43
100	97.90±0.094	97.90±5.87	97.11±0.110	97.11±5.76
FLX
10	07.06±0.068	70.60±1.67	07.87±0.141	78.70±2.35
50	47.04±0.086	94.08±3.16	46.02±0.046	92.04±4.03
100	97.07±0.141	97.07±4.0	98.60±0.127	98.60±5.83

¹Average of six replicate determinations and standard deviation; ²RSD: relative standard deviation.